Comparing the effect of Verapamil and triamcinolon in Hypertrophic scar treatment

Comparative survey on the effect of intralesional verapamil and triamcinolon on Hypertrophic scar and keloid in Rasul Aakram hospital in 94-95

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016010425539N5

Enrollment

Registered

2016-02-07

Start date

2016-02-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic scar. Keloid scar

Interventions

Intervention 1: Intralesional verapamil, vial 2/5 mg, monthly for 3months. Intervention 2: Intralesional triamcinolone, injectable suspension 40mg, 50% concentration, monthly for 3 month.

Treatment - Drugs

Intralesional verapamil, vial 2/5 mg, monthly for 3months.

Intralesional triamcinolone, injectable suspension 40mg, 50% concentration, monthly for 3 month.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hypertrophic scar and keloid which had not any other treatment and after accept of survey condition to come montly for enjection.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hypertrophic scar. Timepoint: The month 0, 1, 2 during treatment and 1 month after treatment. Method of measurement: The highest elevation of hypertrophic scar with calliper and ruler.	—

Secondary

Measure	Time frame
Patient satisfaction from treatment. Timepoint: After treatment. Method of measurement: The percentage and score of the patient to treatment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Nokandeh

Iran University of Medical Sciences

Nokandeh_maryam@yahoo.com+98 21 64351

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026